Monte Rosa Therapeutics revealed preclinical data showing MRT-8102, a novel molecular glue degrader targeting NEK7, effectively reduces inflammation in gout models. The drug inhibited inflammasome activation in human cells and decreased joint swelling in a rabbit gout model, outperforming some existing treatments. These results support the initiation of the Phase 2 GEMINI-1 trial in Q4 2026, aiming to prevent gout flare recurrence, with initial data expected in H2 2027. MRT-8102 offers a new oral treatment approach for gout by selectively degrading NEK7, a key protein in inflammation pathways.
Monte Rosa Therapeutics' preclinical data on MRT-8102 in gout provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 108 rose and 26 fell today. Notable movers include FLNA at USD 0.48 with a 1-day change of +6.01%, LFST at USD 12.99 down 5.66%, and IONS at USD 37.25 down 5.50%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
